{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:38:20Z","timestamp":1792787900026,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Science and Technology Program Project of Tongzhou District, Beijing","award":["WS2023029"],"award-info":[{"award-number":["WS2023029"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-11067-2","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T05:24:06Z","timestamp":1747027446000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Prevalence of bedaquiline resistance in patients with drug-resistant tuberculosis: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Xinyang","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingtao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"11067_CR1","unstructured":"Global tuberculosis report 2024. (accessed 3 December 2024). https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2024"},{"key":"11067_CR2","doi-asserted-by":"crossref","unstructured":"Mahajan R, Bedaquiline. First FDA-approved tuberculosis drug in 40 years. Int J Appl Basic Med Res. 2013;3(1):1\u20132.","DOI":"10.4103\/2229-516X.112228"},{"key":"11067_CR3","unstructured":"WHO Guidelines Approved by the Guidelines Review Committee. The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance. Geneva: World Health Organization Copyright \u00a9 World Health Organization 2013.; 2013."},{"key":"11067_CR4","unstructured":"WHO Guidelines Approved by the Guidelines Review Committee. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva: World Health Organization Copyright \u00a9 World Health Organization 2014.; 2014."},{"key":"11067_CR5","unstructured":"WHO Guidelines Approved by the Guidelines Review Committee. WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update. Geneva: World Health Organization Copyright \u00a9 World Health Organization 2016.; 2016."},{"key":"11067_CR6","unstructured":"WHO Guidelines Approved by the Guidelines Review Committee. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization \u00a9 World Health Organization 2019.; 2019."},{"issue":"2","key":"11067_CR7","doi-asserted-by":"publisher","first-page":"e20210384","DOI":"10.36416\/1806-3756\/e20210384","volume":"48","author":"H Hatami","year":"2022","unstructured":"Hatami H, Sotgiu G, Bostanghadiri N, Abadi SSD, Mesgarpour B, Goudarzi H, et al. Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis. J Bras Pneumol. 2022;48(2):e20210384.","journal-title":"J Bras Pneumol"},{"key":"11067_CR8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.tube.2019.06.005","volume":"117","author":"H Patel","year":"2019","unstructured":"Patel H, Pawara R, Pawara K, Ahmed F, Shirkhedkar A, Surana S. A structural insight of bedaquiline for the cardiotoxicity and hepatotoxicity. Tuberculosis (Edinb). 2019;117:79\u201384.","journal-title":"Tuberculosis (Edinb)"},{"issue":"10","key":"11067_CR9","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1093\/cid\/ciac252","volume":"75","author":"JA Hughes","year":"2022","unstructured":"Hughes JA, Solans BP, Draper HR, Schaaf HS, Winckler JL, van der Laan L, et al. Pharmacokinetics and safety of bedaquiline in human immunodeficiency virus (HIV)-Positive and negative older children and adolescents with Rifampicin-Resistant tuberculosis. Clin Infect Dis. 2022;75(10):1772\u201380.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"11067_CR10","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1124\/dmd.113.056119","volume":"42","author":"K Liu","year":"2014","unstructured":"Liu K, Li F, Lu J, Liu S, Dorko K, Xie W, et al. Bedaquiline metabolism: enzymes and novel metabolites. Drug Metab Dispos. 2014;42(5):863\u20136.","journal-title":"Drug Metab Dispos"},{"key":"11067_CR11","doi-asserted-by":"crossref","unstructured":"Falzon D, Sch\u00fcnemann HJ, Harausz E, Gonz\u00e1lez-Angulo L, Lienhardt C, Jaramillo E et al. World health organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J. 2017;49(3).","DOI":"10.1183\/13993003.02308-2016"},{"issue":"9","key":"11067_CR12","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1093\/cid\/ciy727","volume":"68","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Fox T, Manning K, Stewart A, Tiffin N, Khomo N, et al. Improved treatment outcomes with bedaquiline when substituted for Second-line injectable agents in Multidrug-resistant tuberculosis: A retrospective cohort study. Clin Infect Dis. 2019;68(9):1522\u20139.","journal-title":"Clin Infect Dis"},{"key":"11067_CR13","doi-asserted-by":"crossref","unstructured":"Veziris N, Bernard C, Guglielmetti L, Le Du D, Marigot-Outtandy D, Jaspard M et al. Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors. Eur Respir J. 2017;49(3).","DOI":"10.1183\/13993003.01719-2016"},{"issue":"4","key":"11067_CR14","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s12088-017-0674-0","volume":"57","author":"P Singh","year":"2017","unstructured":"Singh P, Kumari R, Lal R. Bedaquiline: fallible hope against drug resistant tuberculosis. Indian J Microbiol. 2017;57(4):371\u20137.","journal-title":"Indian J Microbiol"},{"issue":"10","key":"11067_CR15","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1093\/cid\/cix992","volume":"66","author":"TVA Nguyen","year":"2018","unstructured":"Nguyen TVA, Anthony RM, Ba\u00f1uls AL, Nguyen TVA, Vu DH, Alffenaar JC. Bedaquiline resistance: its emergence, mechanism, and prevention. Clin Infect Dis. 2018;66(10):1625\u201330.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"11067_CR16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/jpids\/piaa139","volume":"10","author":"T Madzgharashvili","year":"2021","unstructured":"Madzgharashvili T, Salindri AD, Magee MJ, Tukvadze N, Avaliani Z, Blumberg HM, et al. Treatment outcomes among pediatric patients with highly Drug-Resistant tuberculosis: the role of new and repurposed Second-Line tuberculosis drugs. J Pediatr Infect Dis Soc. 2021;10(4):457\u201367.","journal-title":"J Pediatr Infect Dis Soc"},{"key":"11067_CR17","unstructured":"Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. 2017. Available from: http:\/\/www.who.int\/tb\/publications\/pmdt_companionhandbook\/en\/"},{"key":"11067_CR18","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"11067_CR19","doi-asserted-by":"crossref","unstructured":"Munn ZMS, Lisy K, Riitano D, Tufanaru C. Chapter 5: Systematic reviews of prevalence and incidence. In: Aromataris E, Munn Z, editors. JBI Manual for Evidence Synthesis JBI. 2020.","DOI":"10.46658\/JBIRM-17-05"},{"issue":"2","key":"11067_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/jrsm.12","volume":"1","author":"M Borenstein","year":"2010","unstructured":"Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1(2):97\u2013111.","journal-title":"Res Synth Methods"},{"issue":"7414","key":"11067_CR21","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"key":"11067_CR22","doi-asserted-by":"crossref","unstructured":"Xu J, Wang B, Hu M, Huo F, Guo S, Jing W et al. Primary Clofazimine and bedaquiline resistance among isolates from patients with Multidrug-Resistant tuberculosis. Antimicrob Agents Chemother. 2017;61(6).","DOI":"10.1128\/AAC.00239-17"},{"key":"11067_CR23","doi-asserted-by":"crossref","unstructured":"Pang Y, Zong Z, Huo F, Jing W, Ma Y, Dong L et al. In Vitro Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine, Moxifloxacin, and Gatifloxacin against Extensively Drug-Resistant Tuberculosis in Beijing, China. Antimicrobial Agents and Chemotherapy. 2017;61(10).","DOI":"10.1128\/AAC.00900-17"},{"issue":"6","key":"11067_CR24","doi-asserted-by":"publisher","first-page":"1902383","DOI":"10.1183\/13993003.02383-2019","volume":"55","author":"C Nimmo","year":"2020","unstructured":"Nimmo C, Millard J, Brien K, Moodley S, Van Dorp L, Lutchminarain K, et al. Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients. Eur Respir J. 2020;55(6):1902383.","journal-title":"Eur Respir J"},{"key":"11067_CR25","doi-asserted-by":"crossref","unstructured":"Ghajavand H, Kargarpour Kamakoli M, Khanipour S, Pourazar Dizaji S, Masoumi M, Rahimi Jamnani F et al. High prevalence of bedaquiline resistance in Treatment-Naive tuberculosis patients and verapamil effectiveness. Antimicrob Agents Chemother. 2019;63(3).","DOI":"10.1128\/AAC.02530-18"},{"key":"11067_CR26","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ijid.2020.07.044","volume":"99","author":"J Yang","year":"2020","unstructured":"Yang J, Pang Y, Zhang T, Xian X, Li Y, Wang R, et al. Molecular characteristics and in vitro susceptibility to bedaquiline of Mycobacterium tuberculosis isolates Circulating in Shaanxi, China. Int J Infect Dis. 2020;99:163\u201370.","journal-title":"Int J Infect Dis"},{"key":"11067_CR27","doi-asserted-by":"crossref","unstructured":"Zheng H, He W, Jiao W, Xia H, Sun L, Wang S et al. Molecular characterization of multidrug-resistant tuberculosis against Levofloxacin, Moxifloxacin, Bedaquiline, linezolid, Clofazimine, and Delamanid in Southwest of China. BMC Infect Dis. 2021;21(1).","DOI":"10.1186\/s12879-021-06024-8"},{"key":"11067_CR28","doi-asserted-by":"crossref","unstructured":"Yao C, Guo H, Li Q, Zhang X, Shang Y, Li T et al. Prevalence of extensively drug-resistant tuberculosis in a Chinese multidrug-resistant TB cohort after redefinition. Antimicrob Resist Infect Control. 2021;10(1).","DOI":"10.1186\/s13756-021-00995-8"},{"key":"11067_CR29","doi-asserted-by":"publisher","first-page":"754249","DOI":"10.3389\/fmicb.2021.754249","volume":"12","author":"SH Wu","year":"2021","unstructured":"Wu SH, Chan HH, Hsiao HC, Jou R. Primary bedaquiline resistance among cases of Drug-Resistant tuberculosis in Taiwan. Front Microbiol. 2021;12:754249.","journal-title":"Front Microbiol"},{"issue":"9","key":"11067_CR30","doi-asserted-by":"publisher","first-page":"e3391","DOI":"10.1093\/cid\/ciaa1002","volume":"73","author":"Y Liu","year":"2021","unstructured":"Liu Y, Gao M, Du J, Wang L, Gao J, Shu W, et al. Reduced susceptibility of Mycobacterium tuberculosis to bedaquiline during antituberculosis treatment and its correlation with clinical outcomes in China. Clin Infect Dis. 2021;73(9):e3391\u20137.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"11067_CR31","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jinf.2021.02.004","volume":"82","author":"G Wang","year":"2021","unstructured":"Wang G, Jiang G, Jing W, Zong Z, Yu X, Chen S, et al. Prevalence and molecular characterizations of seven additional drug resistance among multidrug-resistant tuberculosis in China: a subsequent study of a National survey. J Infect. 2021;82(3):371\u20137.","journal-title":"J Infect"},{"key":"11067_CR32","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jgar.2021.06.007","volume":"26","author":"W He","year":"2021","unstructured":"He W, Liu C, Liu D, Ma A, Song Y, He P, et al. Prevalence of mycobacterium tuberculosis resistant to bedaquiline and Delamanid in China. J Global Antimicrob Resist. 2021;26:241\u20138.","journal-title":"J Global Antimicrob Resist"},{"key":"11067_CR33","doi-asserted-by":"crossref","unstructured":"Pai H, Ndjeka N, Mbuagbaw L, Kaniga K, Birmingham E, Mao G et al. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis. BMC Infect Dis. 2022;22(1).","DOI":"10.1186\/s12879-022-07861-x"},{"issue":"3","key":"11067_CR34","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/QAI.0000000000002940","volume":"90","author":"MR O\u2019Donnell","year":"2022","unstructured":"O\u2019Donnell MR, Padayatchi N, Wolf A, Zelnick J, Daftary A, Orrell C, et al. Bedaquiline adherence measured by electronic dose monitoring predicts clinical outcomes in the treatment of patients with Multidrug-Resistant tuberculosis and HIV\/AIDS. Jaids-Journal Acquir Immune Defic Syndr. 2022;90(3):325\u201332.","journal-title":"Jaids-Journal Acquir Immune Defic Syndr"},{"issue":"7","key":"11067_CR35","doi-asserted-by":"publisher","first-page":"658","DOI":"10.5588\/ijtld.21.0631","volume":"26","author":"P Nair","year":"2022","unstructured":"Nair P, Hasan T, Zaw KK, Allamuratova S, Ismailov A, Mendonca P, et al. Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan. Int J Tuberculosis Lung Disease. 2022;26(7):658\u201363.","journal-title":"Int J Tuberculosis Lung Disease"},{"issue":"4","key":"11067_CR36","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S1473-3099(21)00470-9","volume":"22","author":"NA Ismail","year":"2022","unstructured":"Ismail NA, Omar SV, Moultrie H, Bhyat Z, Conradie F, Enwerem M, et al. Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. Lancet Infect Dis. 2022;22(4):496\u2013506.","journal-title":"Lancet Infect Dis"},{"key":"11067_CR37","doi-asserted-by":"crossref","unstructured":"Chesov E, Chesov D, Maurer FP, Andres S, Utpatel C, Barilar I et al. Emergence of bedaquiline resistance in a high tuberculosis burden country. Eur Respir J. 2022;59(3).","DOI":"10.1183\/13993003.00621-2021"},{"key":"11067_CR38","doi-asserted-by":"crossref","unstructured":"Derendinger B, Dippenaar A, de Vos M, Huo S, Alberts R, Tadokera R et al. High frequency of bedaquiline resistance in programmatically treated drug-resistant TB patients with sustained culture-positivity in Cape Town, South Africa. 2022.","DOI":"10.1101\/2022.11.14.22282167"},{"issue":"1","key":"11067_CR39","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1080\/22221751.2022.2099304","volume":"11","author":"K Trisakul","year":"2022","unstructured":"Trisakul K, Nonghanphithak D, Chaiyachat P, Kaewprasert O, Sakmongkoljit K, Reechaipichitkul W, et al. High clustering rate and genotypic drug-susceptibility screening for the newly recommended anti-tuberculosis drugs among global extensively drug-resistant Mycobacterium tuberculosis isolates. Emerg Microbes Infect. 2022;11(1):1857\u201366.","journal-title":"Emerg Microbes Infect"},{"key":"11067_CR40","doi-asserted-by":"publisher","first-page":"6951","DOI":"10.2147\/IDR.S429003","volume":"16","author":"E Tong","year":"2023","unstructured":"Tong E, Zhou Y, Liu Z, Zhu Y, Zhang M, Wu K, et al. Bedaquiline resistance and molecular characterization of Rifampicin-Resistant Mycobacterium Tuberculosis isolates in Zhejiang, China. Infect Drug Resist. 2023;16:6951\u201363.","journal-title":"Infect Drug Resist"},{"issue":"5","key":"11067_CR41","doi-asserted-by":"publisher","first-page":"381","DOI":"10.5588\/ijtld.22.0536","volume":"27","author":"S Moe","year":"2023","unstructured":"Moe S, Rekart ML, Hernandez D, Sholpan A, Ismailov A, Oluya M, et al. Primary bedaquiline resistance in Karakalpakstan, Uzbekistan. Int J Tuberc Lung Dis. 2023;27(5):381\u20136.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"11067_CR42","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12941-023-00568-0","volume":"22","author":"Y Hu","year":"2023","unstructured":"Hu Y, Fan J, Zhu D, Liu W, Li F, Li T, et al. Investigation of bedaquiline resistance and genetic mutations in multi-drug resistant Mycobacterium tuberculosis clinical isolates in Chongqing, China. Ann Clin Microbiol Antimicrob. 2023;22(1):19.","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"11067_CR43","doi-asserted-by":"publisher","first-page":"7587","DOI":"10.2147\/IDR.S440711","volume":"16","author":"Y Guo","year":"2023","unstructured":"Guo Y, Yang J, Wang W, Wu X, Wan B, Wang H, et al. Bedaquiline, Delamanid, linezolid, Clofazimine, and capreomycin MIC distributions for drug resistance Mycobacterium tuberculosis in Shanghai, China. Infect Drug Resist. 2023;16:7587\u201395.","journal-title":"Infect Drug Resist"},{"issue":"10","key":"11067_CR44","doi-asserted-by":"publisher","first-page":"e0002283","DOI":"10.1371\/journal.pgph.0002283","volume":"3","author":"J Timm","year":"2023","unstructured":"Timm J, Bateson A, Solanki P, Paleckyte A, Witney AA, Rofael SAD, et al. Baseline and acquired resistance to Bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid. PLOS Global Public Health. 2023;3(10):e0002283\u2013e.","journal-title":"PLOS Global Public Health"},{"key":"11067_CR45","doi-asserted-by":"publisher","first-page":"100674","DOI":"10.1016\/j.lana.2024.100674","volume":"31","author":"C Utpatel","year":"2024","unstructured":"Utpatel C, Zavaleta M, Rojas-Bolivar D, Muhlbach A, Picoy J, Portugal W, et al. Prison as a driver of recent transmissions of multidrug-resistant tuberculosis in Callao, Peru: a cross-sectional study. Lancet Reg Health Americas. 2024;31:100674.","journal-title":"Lancet Reg Health Americas"},{"issue":"3","key":"11067_CR46","doi-asserted-by":"publisher","first-page":"e0374923","DOI":"10.1128\/spectrum.03749-23","volume":"12","author":"T Umpeleva","year":"2024","unstructured":"Umpeleva T, Chetverikova E, Belyaev D, Eremeeva N, Boteva T, Golubeva L, et al. Identification of genetic determinants of bedaquiline resistance in Mycobacterium tuberculosis in ural region, Russia. Microbiol Spectr. 2024;12(3):e0374923.","journal-title":"Microbiol Spectr"},{"issue":"4","key":"11067_CR47","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1093\/cid\/ciad694","volume":"78","author":"L Mikiashvili","year":"2024","unstructured":"Mikiashvili L, Kempker RR, Chakhaia TS, Bablishvili N, Avaliani Z, Lomtadze N, et al. Impact of prior tuberculosis treatment with new\/companion drugs on clinical outcomes in patients receiving concomitant bedaquiline and Delamanid for Multidrug- and Rifampicin-Resistant tuberculosis. Clin Infect Dis. 2024;78(4):1043\u201352.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"11067_CR48","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/cid\/ciad596","volume":"78","author":"TS Brown","year":"2024","unstructured":"Brown TS, Tang L, Omar SV, Joseph L, Meintjes G, Maartens G, et al. Genotype-Phenotype characterization of serial Mycobacterium tuberculosis isolates in Bedaquiline-Resistant Tuberculosis. Clin Infect Dis. 2024;78(2):269\u201376.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"11067_CR49","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1473-3099(23)00498-X","volume":"24","author":"I Barilar","year":"2024","unstructured":"Barilar I, Fernando T, Utpatel C, Abujate C, Madeira CM, Jose B, et al. Emergence of bedaquiline-resistant tuberculosis and of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis strains with RpoB Ile491Phe mutation not detected by Xpert MTB\/RIF in Mozambique: a retrospective observational study. Lancet Infect Dis. 2024;24(3):297\u2013307.","journal-title":"Lancet Infect Dis"},{"key":"11067_CR50","doi-asserted-by":"publisher","first-page":"2037961","DOI":"10.1155\/2024\/2037961","volume":"2024","author":"A Rukmana","year":"2024","unstructured":"Rukmana A, Gozali C, Erlina L. Mycobacterium tuberculosis lineage distribution using whole-genome sequencing and Bedaquiline, Clofazimine, and linezolid phenotypic profiles among rifampicin-resistant isolates from West Java, Indonesia. Int J Microbiol. 2024;2024:2037961.","journal-title":"Int J Microbiol"},{"issue":"1","key":"11067_CR51","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13756-024-01482-6","volume":"13","author":"W Gao","year":"2024","unstructured":"Gao W, Wang W, Li J, Gao Y, Zhang S, Lei H, et al. Drug-resistance characteristics, genetic diversity, and transmission dynamics of multidrug-resistant or rifampicin-resistant mycobacterium tuberculosis from 2019 to 2021 in Sichuan, China. Antimicrob Resist Infect Control. 2024;13(1):125.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"1","key":"11067_CR52","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jiph.2023.11.018","volume":"17","author":"S Li","year":"2024","unstructured":"Li S, Tan Y, Deng Y, Bai G, Huang M, Shang Y, et al. The emerging threat of fluroquinolone-, bedaquiline-, and linezolid-resistant Mycobacterium tuberculosis in China: observations on surveillance data. J Infect Public Health. 2024;17(1):137\u201342.","journal-title":"J Infect Public Health"},{"issue":"2","key":"11067_CR53","doi-asserted-by":"publisher","first-page":"dlac029","DOI":"10.1093\/jacamr\/dlac029","volume":"4","author":"JS Mallick","year":"2022","unstructured":"Mallick JS, Nair P, Abbew ET, Van Deun A, Decroo T. Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review. JAC Antimicrob Resist. 2022;4(2):dlac029.","journal-title":"JAC Antimicrob Resist"},{"key":"11067_CR54","unstructured":"[Chinese expert consensus on multidrug-resistant tuberculosis and Rifampicin-resistant tuberculosis treatment]. Zhonghua Jie He He Hu Xi Za Zhi. 2019;42(10):733\u201349."},{"key":"11067_CR55","doi-asserted-by":"crossref","unstructured":"Guglielmetti L. Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity? Eur Respir J. 2017;49(5).","DOI":"10.1183\/13993003.00738-2017"},{"key":"11067_CR56","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ijid.2021.08.055","volume":"111","author":"L Fu","year":"2021","unstructured":"Fu L, Weng T, Sun F, Zhang P, Li H, Li Y, et al. Insignificant difference in culture conversion between bedaquiline-containing and bedaquiline-free all-oral short regimens for multidrug-resistant tuberculosis. Int J Infect Dis. 2021;111:138\u201347.","journal-title":"Int J Infect Dis"},{"issue":"11","key":"11067_CR57","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1093\/cid\/ciab335","volume":"73","author":"JCM Brust","year":"2021","unstructured":"Brust JCM, Gandhi NR, Wasserman S, Maartens G, Omar SV, Ismail NA, et al. Effectiveness and cardiac safety of Bedaquiline-Based therapy for Drug-Resistant tuberculosis: A prospective cohort study. Clin Infect Dis. 2021;73(11):2083\u201392.","journal-title":"Clin Infect Dis"},{"key":"11067_CR58","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.ijid.2020.10.081","volume":"102","author":"Y Liu","year":"2021","unstructured":"Liu Y, Gao J, Du J, Shu W, Wang L, Wang Y, et al. Acquisition of Clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis. Int J Infect Dis. 2021;102:392\u20136.","journal-title":"Int J Infect Dis"},{"issue":"11","key":"11067_CR59","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1111\/j.1469-0691.2011.03716.x","volume":"18","author":"HB Xu","year":"2012","unstructured":"Xu HB, Jiang RH, Xiao HP. Clofazimine in the treatment of multidrug-resistant tuberculosis. Clin Microbiol Infect. 2012;18(11):1104\u201310.","journal-title":"Clin Microbiol Infect"},{"key":"11067_CR60","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ebiom.2018.01.005","volume":"28","author":"NA Ismail","year":"2018","unstructured":"Ismail NA, Omar SV, Joseph L, Govender N, Blows L, Ismail F, et al. Defining bedaquiline susceptibility, resistance, Cross-Resistance and associated genetic determinants: A retrospective cohort study. EBioMedicine. 2018;28:136\u201342.","journal-title":"EBioMedicine"},{"issue":"5","key":"11067_CR61","doi-asserted-by":"publisher","first-page":"e358","DOI":"10.1016\/S2666-5247(23)00002-2","volume":"4","author":"L Sonnenkalb","year":"2023","unstructured":"Sonnenkalb L, Carter JJ, Spitaleri A, Iqbal Z, Hunt M, Malone KM, et al. Bedaquiline and Clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis. Lancet Microbe. 2023;4(5):e358\u201368.","journal-title":"Lancet Microbe"},{"issue":"1\u20132","key":"11067_CR62","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ymgme.2013.04.024","volume":"110","author":"M Morey","year":"2013","unstructured":"Morey M, Fern\u00e1ndez-Marmiesse A, Casti\u00f1eiras D, Fraga JM, Couce ML, Cocho JA. A glimpse into past, present, and future DNA sequencing. Mol Genet Metab. 2013;110(1\u20132):3\u201324.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"11067_CR63","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13073-019-0660-8","volume":"11","author":"KA Cohen","year":"2019","unstructured":"Cohen KA, Manson AL, Desjardins CA, Abeel T, Earl AM. Deciphering drug resistance in Mycobacterium tuberculosis using whole-genome sequencing: progress, promise, and challenges. Genome Med. 2019;11(1):45.","journal-title":"Genome Med"},{"key":"11067_CR64","doi-asserted-by":"crossref","unstructured":"Nieto Ramirez LM, Quintero Vargas K, Diaz G. Whole genome sequencing for the analysis of drug resistant strains of Mycobacterium tuberculosis: A systematic review for bedaquiline and Delamanid. Antibiot (Basel). 2020;9(3).","DOI":"10.3390\/antibiotics9030133"},{"key":"11067_CR65","doi-asserted-by":"publisher","first-page":"100582","DOI":"10.1016\/j.nmni.2019.100582","volume":"31","author":"F Zakham","year":"2019","unstructured":"Zakham F, Laurent S, Esteves Carreira AL, Corbaz A, Bertelli C, Masserey E, et al. Whole-genome sequencing for rapid, reliable and routine investigation of Mycobacterium tuberculosis transmission in local communities. New Microbes New Infect. 2019;31:100582.","journal-title":"New Microbes New Infect"},{"issue":"5","key":"11067_CR66","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.cmi.2021.09.014","volume":"28","author":"D Liu","year":"2022","unstructured":"Liu D, Huang F, Zhang G, He W, Ou X, He P, et al. Whole-genome sequencing for surveillance of tuberculosis drug resistance and determination of resistance level in China. Clin Microbiol Infect. 2022;28(5):731.e9\u2013e15.","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"11067_CR67","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ijantimicag.2019.04.004","volume":"54","author":"K Faksri","year":"2019","unstructured":"Faksri K, Kaewprasert O, Ong RT, Suriyaphol P, Prammananan T, Teo YY, et al. Comparisons of whole-genome sequencing and phenotypic drug susceptibility testing for Mycobacterium tuberculosis causing MDR-TB and XDR-TB in Thailand. Int J Antimicrob Agents. 2019;54(2):109\u201316.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"11067_CR68","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1016\/S2666-5247(23)00317-8","volume":"5","author":"C Nimmo","year":"2024","unstructured":"Nimmo C, Bionghi N, Cummings MJ, Perumal R, Hopson M, Al Jubaer S, et al. Opportunities and limitations of genomics for diagnosing bedaquiline-resistant tuberculosis: a systematic review and individual isolate meta-analysis. Lancet Microbe. 2024;5(2):e164\u201372.","journal-title":"Lancet Microbe"},{"issue":"11","key":"11067_CR69","doi-asserted-by":"publisher","first-page":"e604","DOI":"10.1016\/S2666-5247(21)00175-0","volume":"2","author":"N Ismail","year":"2021","unstructured":"Ismail N, Rivi\u00e8re E, Limberis J, Huo S, Metcalfe JZ, Warren RM, et al. Genetic variants and their association with phenotypic resistance to bedaquiline in Mycobacterium tuberculosis: a systematic review and individual isolate data analysis. Lancet Microbe. 2021;2(11):e604\u201316.","journal-title":"Lancet Microbe"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11067-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11067-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11067-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T06:03:49Z","timestamp":1747029829000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11067-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11067"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11067-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"689"}}